BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon. 2016;16:e37089. [PMID: 27275164 DOI: 10.5812/hepatmon.37089] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Jonaidi-jafari N, Rezaee-zavareh MS, Tavallaei-nosratabadi J, Ajudani R, Ramezani-binabaj M, Karimi-sari H, Izadi M, Ranjbar R, Miri SM, Alavian SM. Occult Hepatitis B Infection in Hepatitis C Patients with Hematological Disorders. Jundishapur J Microbiol 2016;10. [DOI: 10.5812/jjm.40816] [Reference Citation Analysis]
2 Alavian SM, Sharafi H. Update on Recommendations for the Clinical Management of Hepatitis C in Iran 2017. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.63956] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
3 Mirzazadeh A, Hosseini-hooshyar S, Shahesmaeili A, Sharafi H, Shafiei M, Zarei J, Mousavian G, Tavakoli F, Ghalekhani N, Shokoohi M, Khezri M, Mehmandoost S, Shojaei MR, Karamouzian M, Briceno A, Morris MD, Alavian SM, Haghdoost A, Sharifi H, Page KA. An on-site community-based model for hepatitis C screening, diagnosis, and treatment among people who inject drugs in Kerman, Iran: The Rostam study. International Journal of Drug Policy 2022;102:103580. [DOI: 10.1016/j.drugpo.2022.103580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Behzadifar M, Azari S, Gorji HA, Martini M, Bragazzi NL. The hepatitis C virus in Iran: health policy, historical, ethical issues and future challenges. J Prev Med Hyg 2020;61:E109-18. [PMID: 32490276 DOI: 10.15167/2421-4248/jpmh2020.61.1.1438] [Reference Citation Analysis]
5 Sharafi H, Alavian SM. The Rising Threat of Hepatocellular Carcinoma in the Middle East and North Africa Region: Results From Global Burden of Disease Study 2017. Clin Liver Dis (Hoboken) 2019;14:219-23. [PMID: 32015873 DOI: 10.1002/cld.890] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
6 Mohazzab-torabi S, Dolatimehr F, Sharafi H, Safi-abadi M, Rezaee-zavareh MS, Bayatpour E, Karimi-sari H, Alavian SM. Treatment of HCV Infection with Direct-Acting Antiviral Agents in Patients with HIV/HCV Co-Infection: A Systematic Review. Hepat Mon 2018;In Press. [DOI: 10.5812/hepatmon.82971] [Reference Citation Analysis]
7 Bayatpoor ME, Karimi-Sari H, Alavian SM. Viral hepatitis elimination should receive more attention from Iranian nurses. Res Nurs Health 2018;41:9-10. [PMID: 29266371 DOI: 10.1002/nur.21847] [Reference Citation Analysis]
8 Fialho R, Pereira M, Harrison N, Rusted J, Whale R. Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C. Psychiatry Res 2017;253:150-7. [PMID: 28365538 DOI: 10.1016/j.psychres.2017.03.049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
9 Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM. The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis. Hepat Mon. 2016;16:e40357. [PMID: 27826320 DOI: 10.5812/hepatmon.40357] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
10 Rajabi A, Sharafi H, Alavian SM. Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis. Harm Reduct J 2021;18:12. [PMID: 33482831 DOI: 10.1186/s12954-020-00441-9] [Reference Citation Analysis]
11 Alavian SM, Sharafi H. Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'. Eur J Gastroenterol Hepatol 2018;30:807-8. [PMID: 29847527 DOI: 10.1097/MEG.0000000000001124] [Reference Citation Analysis]
12 Sharafi H, Poustchi H, Azimian F, Tamadoni B, Ramezani R, Gouya MM, Sheikh M, Hashemi F, Tashakorian M, Alasvand R, Alavian SM, Merat S. Performance of a rapid diagnostic test for screening of hepatitis C in a real-life prison setting. J Clin Virol 2019;113:20-3. [PMID: 30825832 DOI: 10.1016/j.jcv.2019.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
13 Lin HM, Wu PS, Hu HS, Chang WC, Wu RH, Tian JN, Chern JH, Yueh A. Development of robust genotype 1a hepatitis C replicons harboring adaptive mutations for facilitating the antiviral drug discovery and study of virus replication. J Virol Methods 2018;259:10-7. [PMID: 29782889 DOI: 10.1016/j.jviromet.2018.05.010] [Reference Citation Analysis]
14 Sharafi H, Alavian SH, Behnava B, Saeid Rezaee-Zavareh M, Nikbin M, Alavian SM. Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study. Caspian J Intern Med 2020;11:41-6. [PMID: 32042385 DOI: 10.22088/cjim.11.1.41] [Reference Citation Analysis]
15 Zamani F, Ajdarkosh H, Safarnezhad-Tameshkel F, Azarkeivan A, Keyvani H, Naserifar F, Vafaeimanesh J. The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors. Indian J Med Microbiol 2018;36:224-9. [PMID: 30084415 DOI: 10.4103/ijmm.IJMM_18_90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
16 Dolatimehr F, Khosravi MH, Rezaee-zavareh MS, Alavian SM. Prevalence of occult HCV infection in hemodialysis and kidney-transplanted patients: a systematic review. Future Virology 2017;12:315-22. [DOI: 10.2217/fvl-2016-0138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Cacoub P. Comment on Nuño Solinís R, et al. "Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence". Infect Dis Ther 2017;6:297-301. [PMID: 28357707 DOI: 10.1007/s40121-017-0155-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Sharafi H, Nikbin M, Alavian SH, Behnava B, Alavian SM. Efficacy and Safety of Generic Sofosbuvir/Ledipasvir Fixed-Dose Combination in Iranian Patients with Chronic Hepatitis C Virus Infection. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.12216] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016;16:e40959. [PMID: 27799966 DOI: 10.5812/hepatmon.guideline] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 7.8] [Reference Citation Analysis]
20 Ziaee M, Hajihosseini M. Hepatitis Awareness Bus: A Model for Finding Unknown Hepatitis B and C Infections. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.11719] [Reference Citation Analysis]
21 Karimi-Sari H, Tajik M, Bayatpoor ME, Alavian SM. Increasing the Awareness of the General Population: An Important Step in Elimination Programs of Viral Hepatitis. Am J Gastroenterol. 2017;112:393-395. [PMID: 28154404 DOI: 10.1038/ajg.2016.534] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
22 Hesamizadeh K, Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Jahanbakhsh Sefidi F. Molecular Epidemiology of Kaposi's Sarcoma-Associated Herpes Virus, and Risk Factors in HIV-infected Patients in Tehran, 2014. Iran Red Crescent Med J 2016;18:e32603. [PMID: 28191343 DOI: 10.5812/ircmj.32603] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Sharafi H, Alavian SM. Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem? World J Hepatol 2018; 10(9): 543-548 [PMID: 30310532 DOI: 10.4254/wjh.v10.i9.543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
24 Rezaee-zavareh MS, Hesamizadeh K, Sharafi H, Alavian SM. Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.12324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
25 Fouad HM, Ahmed Mohamed A, Sabry M, Abdel Aziz H, Eysa B, Rabea M. The Effectiveness of Ledipasvir/Sofosbuvir in Youth With Genotype 4 Hepatitis C Virus: A Single Egyptian Center Study. Pediatr Infect Dis J. 2019;38:22-25. [PMID: 30234791 DOI: 10.1097/inf.0000000000002189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
26 Rashti R, Sharafi H, Alavian SM, Moradi Y, Mohamadi Bolbanabad A, Moradi G. Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers. Pathogens 2020;9:E432. [PMID: 32486342 DOI: 10.3390/pathogens9060432] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
27 Miri SM, Sharafi H, Pouryasin A, Behnava B, Keshvari M, Salimi S, Karimi Elizee P, Alavian SM. The Role of Polymorphisms Near IFNL3 Gene as Predictors of Residual HCV RNA in Buffy Coat after Successful Antiviral Therapy. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.46539] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
28 Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. Street and labour children; special group for elimination of viral hepatitis in Iran. Sex Transm Infect 2017;93:38. [PMID: 28100760 DOI: 10.1136/sextrans-2016-052890] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepat Mon 2016;16:e41077. [PMID: 27826322 DOI: 10.5812/hepatmon.41077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
30 Karimi-Sari H, Bayatpoor ME, Aftabi Khotbesara M, Ebrahimi MS, Sattari Z, Sattari P, Saberi Shakib N, Taheri H, Abdolrahim Poor Heravi S, Dinizadeh M, Vahed P, Shirsavar K, Hosseini H, Rashvand S, Jalaei D, Azarafraz M, Naderi M, Pourzakaria M, Firoozbakht M, Khosravi MH, Alavian SM. Knowledge, attitude, and practice of Iranian health sciences students regarding hepatitis B and C virus infections: A national survey. Am J Infect Control 2017;45:e135-41. [PMID: 28893448 DOI: 10.1016/j.ajic.2017.07.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
31 Sharafi H, Ghalamkari S, Hassanshahi A, Alavian SM. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank. Microb Drug Resist 2019;25:1072-9. [PMID: 31021305 DOI: 10.1089/mdr.2018.0358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Hesamizadeh K, Tavakoli A, Nikbin M. Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran. Med J Islam Repub Iran 2019;33:63. [PMID: 31456987 DOI: 10.34171/mjiri.33.63] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Torres-Cornejo A, Lauer GM. Hurdles to the Development of Effective HBV Immunotherapies and HCV Vaccines. Pathog Immun 2017;2:102-25. [PMID: 28664194 DOI: 10.20411/pai.v2i1.201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
34 Alavian SM, Rezaee-Zavareh MS. The Middle East and hepatitis C virus infection: does it need special attention? Lancet Infect Dis. 2016;16:1006-1007. [PMID: 27684342 DOI: 10.1016/s1473-3099(16)30264-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
35 Miri SM, Sharafi H, Salimi S, Bokharaei-salim F, Behnava B, Keshvari M, Karimi Elizee P, Keyvani H, Alavian SM. Assessment of Hepatitis C Virus RNA in Peripheral Blood Mononuclear Cells as a Predictor of Response to Pegylated-Interferon and Ribavirin: A Cohort Study. Iran Red Crescent Med J 2017;19. [DOI: 10.5812/ircmj.46578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
36 Hesamizadeh K, Alavian SM, Najafi Tireh Shabankareh A, Sharafi H. Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review. Hepat Mon 2016;16:e42938. [PMID: 28123445 DOI: 10.5812/hepatmon.42938] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
37 Khosravi A, Karimi-Sari H, Abedi-Andani M, Behnava B, Namvar A, Anvar A, Alavian SM. Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C-infected patients with thalassemia. J Med Virol 2019;91:419-27. [PMID: 30204230 DOI: 10.1002/jmv.25314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
38 Dolatimehr F, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM, Behnava B, Gholami-Fesharaki M, Sharafi H. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis. Daru 2017;25:11. [PMID: 28427463 DOI: 10.1186/s40199-017-0177-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
39 Mirminachi B, Mohammadi Z, Merat S, Neishabouri A, Sharifi AH, Alavian SH, Poustchi H, Malekzadeh R. Update on the Prevalence of Hepatitis C Virus Infection Among Iranian General Population: A Systematic Review and Meta-Analysis. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.42291] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
40 Karimi-sari H, Tajik M, Bayatpoor ME, Sharafi H, Alavian SM. Public Awareness Campaign and Knowledge of Iranian (Bio)Medical Students Regarding Hepatitis B and C Infections. Hepat Mon 2017;17. [DOI: 10.5812/hepatmon.45929] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
41 Rezaee-Zavareh MS, Alavian SM. Letter: the efficacy of interferon-free regimens in HCV-related Child C cirrhosis needs careful interpretation. Aliment Pharmacol Ther 2017;46:76. [PMID: 28589589 DOI: 10.1111/apt.14083] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Habibi N, Nassiri-toosi M, Sharafi H, Alavian SM, Shams-ghahfarokhi M, Razzaghi-abyaneh M. Aflatoxin B 1 exposure and the risk of hepatocellular carcinoma in Iranian carriers of viral hepatitis B and C. Toxin Reviews 2019;38:234-9. [DOI: 10.1080/15569543.2018.1446027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
43 Yang Y, Wu FP, Wang WJ, Shi JJ, Li YP, Zhang X, Dang SS. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019; 25(44): 6551-6560 [PMID: 31802834 DOI: 10.3748/wjg.v25.i44.6551] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
44 Karimi-Sari H, Bayatpoor ME, Alavian SM. Awareness Campaign in (bio)Medical Students in Iran: a model for increasing the knowledge regarding hepatitis B and C. Clin Microbiol Infect 2017;23:418-9. [PMID: 27956270 DOI: 10.1016/j.cmi.2016.11.022] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
45 Karimi-Sari H, Ghafari Z, Alavian SM. Hepatitis C screening in patients with oral lichen planus. J Investig Clin Dent 2018;9:e12350. [PMID: 29971956 DOI: 10.1111/jicd.12350] [Reference Citation Analysis]
46 Keshvari M, Alavian SM, Behnava B, Pouryasin A, Craig JC, Sharafi H. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. J Clin Lab Anal 2017;31. [PMID: 27735085 DOI: 10.1002/jcla.22063] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
47 Lynch SM, Wu GY. Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy. J Clin Transl Hepatol 2016;4:310-9. [PMID: 28097100 DOI: 10.14218/JCTH.2016.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 0.3] [Reference Citation Analysis]
48 Sallam M, Batarseh R, Natsheh A, Abbadi J, Al-Fraihat E, Yaseen A, Kaddomi D, Khamees N, Mahafzah A, Şahin GÖ. An update on hepatitis C virus genotype distribution in Jordan: a 12-year retrospective study from a tertiary care teaching hospital in Amman. BMC Infect Dis 2019;20:3. [PMID: 31892307 DOI: 10.1186/s12879-019-4735-3] [Reference Citation Analysis]